An overview of disease treatment strategies targeting the alternative splicing of pre-mRNA
10.16438/j.0513-4870.2023-0586
- VernacularTitle:靶向pre-mRNA的选择性剪接过程的疾病治疗策略研究概述
- Author:
Xin-ru GUO
;
Xiang ZHANG
- Publication Type:Research Article
- Keywords:
pre-mRNA;
alternative splicing;
splicing modification;
genetic metabolic disease;
cancer
- From:
Acta Pharmaceutica Sinica
2023;58(12):3557-3571
- CountryChina
- Language:Chinese
-
Abstract:
Alternative splicing of pre-messenger RNA (pre-mRNA) is a crucial mechanism for the diversity of the human transcriptome and proteome. Alternative splicing is a complex gene regulation process. Whole-transcriptome analysis shows that 95% of human exonic genes are alternatively spliced, involving various cis-acting elements and trans-acting factors. Any changes in any component or step may cause erroneous splicing events and lead to the occurrence of various related diseases. In addition to gene replacement therapy that directly changes the splicing results, RNA splicing modification is expected to become a new therapeutic strategy to alleviate or treat diseases by targeting and correcting abnormal pre-mRNA splicing. Splicing modification tools currently developed including RNA trans-splicing, antisense oligonucleotides, small interfering RNA, and small molecule drugs can correct abnormal splicing through different ways. This article reviews the resent progress of epigenetic regulation of pre-mRNA alternative splicing in recent years, and discusses the occurrence and regulation of alternative splicing, the types of diseases caused by related splicing defects, and the current-used tools for targeting and altering splicing. The importance of splicing modification strategies in the future treatment of human diseases is envisioned.
